Organizational stigma: taking stock and opening new areas for research

Autor: Hudson, BA, Patterson, KDW, Roulet, TJ, Helms, WS, Elsbach, K

Since its introduction as a concept, organizational stigma has become central to explaining how organizations or industries become tainted, and how they overcome and manage such taint. In this introduction to the Special Issue on organizational stigm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e16f7b9233f17e84fa24fb2b579fde1
https://www.repository.cam.ac.uk/handle/1810/341654

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.

Autor: Akinboro O; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Larkins E; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Pai-Scherf LH; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Mathieu LN; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Ren Y; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Cheng J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Fiero MH; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Fu W; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Bi Y; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Kalavar S; Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Jafri S; Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Mishra-Kalyani PS; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Fourie Zirkelbach J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Li H; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Zhao H; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., He K; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Helms WS; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Chuk MK; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Wang M; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Bulatao I; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Herz J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Osborn BL; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Xu Y; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Liu J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Gong Y; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Sickafuse S; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Cohen R; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Donoghue M; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Pazdur R; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Beaver JA; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland., Singh H; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jun 01; Vol. 28 (11), pp. 2221-2228.

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.

Autor: Kim J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. janice.kim@fda.hhs.gov., Bradford D; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Larkins E; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Pai-Scherf LH; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Chatterjee S; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Mishra-Kalyani PS; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Wearne E; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Helms WS; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Ayyoub A; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Bi Y; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Sun J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Charlab R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Liu J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Zhao H; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Liang D; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland., Ghosh S; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland., Philip R; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland., Pazdur R; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Beaver JA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Singh H; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Oct 15; Vol. 27 (20), pp. 5452-5456. Date of Electronic Publication: 2021 May 27.

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.

Autor: Singh S; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. sonia.singh@fda.hhs.gov., Jaigirdar AA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Mulkey F; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Cheng J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Hamed SS; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Li Y; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Liu J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Zhao H; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Goheer A; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Helms WS; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Wang X; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Agarwal R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Pragani R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Korsah K; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Tang S; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Leighton J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Rahman A; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland., Beaver JA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Pazdur R; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Singh H; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 May 01; Vol. 27 (9), pp. 2378-2382. Date of Electronic Publication: 2020 Dec 07.